Reading between the lines of J&J's $1.75bn Alios buy

Johnson & Johnson highlighted the Phase II therapy AL-8178 for respiratory syncytial virus (RSV) on 30 September when it announced the $1.75bn acquisition of Alios BioPharma, but the most valuable aspect of the deal may be the privately-held company's preclinical hepatitis C virus (HCV) programs.